Rapid Micro Biosystems, Inc.

RPID Healthcare Medical Devices

Rapid Micro Biosystems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.6 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.9%, EPS was flat and free cash flow fell 24.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

0.76 0.09 −10.59%
Market cap
$42.4M
P/E
0.0×
Fwd P/E
−2.1×
Dividend yield
—
F-score
3/9
Altman Z
−8.86
Beneish M
−5.06
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
2 2 3 3

+8 more TTM periods

ROE
(141.65%) (116.74%) (86.82%) (68.83%)
ROA
(76.40%) (67.84%) (54.47%) (46.56%)
ROIC
(181.64%) (187.79%) (214.45%) (129.52%)
Return on Tangible Assets
(141.15%) (128.96%) (91.23%) (70.32%)
Average Days of Receivables
57.23 67.59 34.06 64.93
Free Cash Flow per Share
(0.84) (0.84) (0.71) (0.86)
Free Cash Flow
(40.39) (37.98) (31.91) (38.58)
Other line items

Show all line items

Columns are period end dates